ArticleThe Journal of infectious diseases2024
Heptavalent O-Antigen Bioconjugate Vaccine Exhibiting Differential Functional Antibody Responses Against Diverse Klebsiella pneumoniae Isolates.
Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study.The Journal of infectious diseases · 2026Trial
- A universally conserved OMV-YidR conjugate nanovaccine confers broad protection against hypervirulent and carbapenem-resistantEmerging microbes & infections · 2026Article
- Maternal vaccination with capsular polysaccharide bioconjugates protects against murineScience advances · 2026Article
- Cross-Serotype Protection of a PstS-YidR Fusion mRNA Vaccine Against Systemic Infection and Endogenous Endophthalmitis Caused by HypervirulentPathogens (Basel, Switzerland) · 2026Article
- Escalating burden and mortality of carbapenem-resistant Klebsiella pneumoniae species complex infections in Bangladeshi infants.npj antimicrobials and resistance · 2026Article
- GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.Scientific reports · 2026Article
- A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs.PNAS nexus · 2026Article
- Article
- Genomic diversity in the critical priority pathogen Klebsiella pneumoniae: global and regional perspectives.BMC microbiology · 2026Article
- The sero-prevalence and virulence determinants ofMicrobiology spectrum · 2026Article
- A potent protein vaccines OmpW induces strong protective immunity against Klebsiella pneumoniae in a mouse model.Medical microbiology and immunology · 2026Article
- Differential virulence and immune recognition ofInfection and immunity · 2026Article
- The TamA protein as a subunit vaccine improves immune protection against highly virulentCurrent research in microbial sciences · 2026Article
- Glycoengineering the Pseudomonas exotoxin A for multi-sequon integration and enhanced bioconjugation efficiency by PglS.Glycobiology · 2025Article
- A multivalent capsule vaccine protects against Klebsiella pneumoniae bloodstream infections in healthy and immunocompromised mice.NPJ vaccines · 2025Article
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- The development of functional opsonophagocytic assays to evaluate antibody responses tomSphere · 2025Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Recent Advances in Bioconjugate Vaccine Development.Vaccines · 2025Review
Corrections and comments
- Update of
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Klebsiella pneumoniae is the leading cause of neonatal sepsis and is increasingly difficult to treat owing to antibiotic resistance. Vaccination represents a tractable approach to combat this resistant bacterium; however, there is currently not a licensed vaccine. Surface polysaccharides, including O-antigens of lipopolysaccharide, have long been attractive candidates for vaccine inclusion. Herein we describe the generation of a bioconjugate vaccine targeting 7 predominant O-antigen subtypes in K. pneumoniae. Each bioconjugate was immunogenic in isolation, with limited cross-reactivity among subtypes. Vaccine-induced antibodies demonstrated varying degrees of binding to a wide variety of K. pneumoniae strains. Furthermore, serum from vaccinated mice induced complement-mediated killing of many of these strains. Finally, increased capsule interfered with the ability of O-antigen antibodies to bind and mediate killing of some K. pneumoniae strains. Taken together, these data indicate that this novel heptavalent O-antigen bioconjugate vaccine formulation exhibits limited efficacy against some, but not all, K. pneumoniae isolates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.